Menu
X

Breast Cancer

ABOUT BREAST CANCER

According to the American Cancer Society, Louisiana has one of the highest cancer mortality rates in the nation. We do not have a higher incidence of most cancers; instead, we have higher death rates. This is due to lack of access to care, delayed diagnosis and treatment, limited educational awareness and low utilization of preventative services. Screening tests can help find cancer at an early stage, before symptoms appear. The earlier abnormal tissue or cancer is discovered, the more options there are for successful treatment. Learn more about breast cancer below.

Geaux Pink logo
GEAUX PINK

If you’re interested in joining the fight against cancer, consider Geaux-ing Pink this October. Geaux Pink is a signature awareness and fundraising event that allows the Cancer Center to partner with individuals, schools, businesses and sports teams to raise funds and awareness around breast cancer. Signing up is easy! Click here to learn how!

Survive Dat
SURVIVEDAT

Although increasing age is a common risk factor for various types of cancer, including breast, young women can still develop breast cancer. Often times, young breast cancer survivors have unique needs compared to older women with breast cancer. SurviveDat is a resource for young breast cancer patients and caregivers.

October is breast cancer awareness month
RISK FACTORS

Some risk factors for breast cancer are not preventable, such as getting older, personal or family history of breast cancer or some non-cancerous breast diseases, while some risk factors can be associated with lifestyle choices. Not being physically active, being overweight or obese after menopause or drinking alcohol can increase your risk. If you have questions about potential risk factors in your life, talk with your doctor.

SYMPTOMS

Possible symptoms of breast cancer may include swelling of all or part of the breast, breast or nipple pain or the nipple turning inward, or a lump in the underarm area. Skin irritation or dimpling, redness, scaliness or thickening of the nipple or breast skin, or nipple discharge other than breast milk are other possible signs. Please consult with your doctor if you experience any of these symptoms.

Source: breastcancer.org

SCREENINGS

WHEN TO GET SCREENED FOR BREAST CANCER

Women should get a clinical breast exam at least every three years, starting in their 20s, and get an annual exam and mammogram starting at 40. Breast self-exam is an option beginning at age 20. See a doctor about any breast changes.

PATIENT STORIES

RUTH PORTILLO, BREAST CANCER SURVIVOR

“When you don’t speak English, you’re always fearful language will be a barrier to your care but that was not the case,” said Ruth. “Now, I tell people to not be afraid and take advantage of the Cancer Center’s free screening services; they will be with you every step of the way. They saved my life.”

Ruth homepage

CLINICAL TRIALS

Clinical trials are research studies that involve human beings in order to test new ways to prevent, detect, diagnose or treat diseases. A drug must be part of a clinical trial before the FDA will approve it to be put on the market. Oncology clinical trials are conducted in order to test new drugs or a new combination of drug treatments, new surgery and radiation therapies and new medical devices.

Every cancer center patient is evaluated for participation in a clinical trial. Those who meet the criteria to participate in clinical research receive a standard of care treatment, but with the added benefit of a trial that may enhance their outcomes.

If interested in volunteering to participate in a clinical research trial, or if you have concerns about the conduct of clinical research, please contact the Clinical Research office at (225) 215-1353, or by email at clinicalresearch@marybird.com.

Trial Number: Alliance A011202

Title: A Randomized Phase III Trial Comparing Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy

Purpose: This randomized phase III trial studies axillary lymph node dissection to see how well it works compared to axillary radiation therapy in treating patients with node-positive breast cancer treated with neoadjuvant chemotherapy followed by surgery. Lymph node dissection may remove cancer cells that have spread to nearby lymph nodes in patients with breast cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. This study will evaluate whether radiation therapy is as effective as lymph node dissection.

Physicians: Drs. Mindy Bowie, and Cecilia Cuntz.

Offered in: Baton Rouge

Trial Number: Alliance A221505

Title: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction

Purpose: This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells that remain after surgery and have fewer side effects.

Physicians: Drs. Katherine Castle, Robert Fields, Maurice King, Renee Levine, Jingya Wang, and Charles Wood; Andrew Elson; Jeffrey Long.

Offered in: Baton Rouge, Covington, Houma

Trial Number: EA1151

Title: Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer

Purpose: This randomized phase III trial studies digital tomosynthesis mammography and digital mammography in screening patients for breast cancer. Screening for breast cancer with tomosynthesis mammography may be superior to digital mammography for breast cancer screening and may help reduce the need for additional imaging or treatment.

Physicians: Dr. James Ruiz

Offered in: Baton Rouge (Woman’s Hospital)

Trial Number: NSABP B-58/MonarchE

Title: A Randomized, Open Label, Phase 3 Study of Ademaciclib Combined with Standard Adjuvant Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Purpose: The purpose of this study is to evaluate the safety and efficacy of the study drug Abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer.

Physicians: Drs. Bryan Bienvenu, Vince CataldoDavid Hanson, Kellie Schmeeckle, Joseph Shows, Siva Yadlapati and Derrick Spell

Offered in: Baton Rouge

Trial Number: A5481082 POLARIS

Title: Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study

Purpose: The objectives of this prospective NIS of Palbociclib in ABC treatment are to describe and analyze Palbociclib prescribing and treatment patterns in routine clinical practice, metastatic breast cancer (MBC) treatment sequencing prior to, during, and after Palbociclib, patient quality of life, geriatric specific assessment; and to explore biomarkers underlying resistance or response mechanisms to Palbociclib treatment.

Physicians:  Drs. Bryan BienvenuDavid HansonKellie SchmeeckleDerrick Spell

Offered in: Baton Rouge

Trial Number: WF-97116

Title: A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairment

Purpose: This study is to compare the safety and effects of Donepezil (Aricept) or if it decreases memory loss after receiving chemotherapy for breast cancer.

Physicians:   Drs. Bryan BienvenuDavid HansonKellie SchmeeckleDerrick SpellJames CarinderJack SauxRobert GambleNaveed KhanVince CataldoJoseph ShowsSiva Yadlapati and Lauren Zatarain

Offered in: Baton Rouge, Covington, Houma

Trial Number: ECOG 2112

Title: A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer

Purpose: This randomized phase III trial studies exemestane and entinostat to see how well they work compared to exemestane alone in treating patients with hormone receptor-positive breast cancer that has spread to nearby tissue or lymph nodes or another place in the body. Estrogen can cause the growth of breast cancer cells. Endocrine therapy using exemestane may fight breast cancer by lowering the amount of estrogen the body makes. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether exemestane is more effective with or without entinostat in treating breast cancer.

Physicians: Drs. Bryan BienvenuVince CataldoDavid HansonKellie SchmeeckleJoseph ShowsDerrick SpellSiva Yadlapati and Lauren ZatarainJames Carinder and Jack SauxRobert Gamble and Naveed Khan.

Offered in: Baton Rouge, Covington, Houma

Trial Number:  NSABP B-55

Title:  A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

Purpose:  Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.

Physicians: Drs. Bryan BienvenuVince CataldoDavid HansonKellie SchmeeckleJoseph ShowsDerrick SpellSiva Yadlapati and Lauren ZatarainRobert Gamble, and Naveed KhanJames Carinder and Jack Saux.

Offered in:  Baton Rouge, Covington, Houma

Trial Number: NRG BR-003

Title: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Purpose: This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether doxorubicin hydrochloride and cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and carboplatin in treating triple-negative breast cancer.

Physicians: Drs. Bryan BienvenuVince CataldoDavid HansonKellie SchmeeckleJoseph ShowsDerrick SpellSiva Yadlapati and Lauren ZatarainRobert Gamble, and Naveed KhanJames Carinder and Jack Saux.

Offered in: Baton Rouge, Covington, Houma

Trial Number: NSABP B-51

Title:  A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Purpose:  This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet known whether comprehensive radiation therapy is more effective than standard radiation therapy in treating patients with breast cancer.

Physicians:  Katherine Castle, Robert Fields, Maurice King, Renee Levine, Jingya Wang and Charles Wood; Andrew Elson;  Jeffrey Long.

Offered in:  Baton Rouge, Covington, Gonzales, Hammond and Houma

Trial Number: A011401

Title: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (BWEL Study)

Purpose: This randomized phase III trial studies whether weight loss in overweight and obese women may prevent breast cancer from coming back (recurrence). Previous studies have found that women who are overweight or obese when their breast cancer is found (diagnosed) have a greater risk of their breast cancer recurring, as compared to women who were thinner when their cancer was diagnosed. This study aims to test whether overweight or obese women who take part in a weight loss program after being diagnosed with breast cancer have a lower rate of cancer recurrence as compared to women who do not take part in the weight loss program. This study will help to show whether weight loss programs should be a part of breast cancer treatment.

Physicians: Drs. Bryan BienvenuVince CataldoRobert FieldsDavid HansonMaurice KingRenee LevineKellie SchmeeckleJoseph ShowsDerrick SpellJingya WangCharles WoodSiva Yadlapati and Lauren Zatarain;  James CarinderAndrew Elson and Jack SauxRobert GambleNaveed Khan and Jeffrey Long.

Offered in: Baton Rouge, Covington, Houma

Trial Number: A011502

Title:  A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial

Purpose: This randomized phase III trial studies how well aspirin works in preventing the cancer from coming back (recurrence) in patients with human epidermal growth factor receptor 2 (HER2) breast cancer after chemotherapy, surgery, and/or radiation therapy. Aspirin is a drug that reduces pain, fever, inflammation, and blood clotting. It is also being studied in cancer prevention. Giving aspirin may reduce the rate of cancer recurrence in patients with breast cancer.

Physicians: Drs. Bryan BienvenuVince CataldoDavid HansonKellie SchmeeckleJoseph ShowsDerrick SpellSiva Yadlapati and Lauren Zatarain;  James Carinder and Jack SauxRobert Gamble and Naveed Khan.

Offered in: Baton Rouge, Covington, Houma

Trial Number: EA1131

Title:  A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy

Purpose: This randomized phase III trial studies how well cisplatin or carboplatin (platinum based chemotherapy) works compared to capecitabine in treating patients with remaining (residual) basal-like triple-negative breast cancer following chemotherapy after surgery (neoadjuvant). Drugs used in chemotherapy, such as cisplatin, carboplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether cisplatin or carboplatin is more effective than capecitabine in treating patients with residual triple negative basal-like breast cancer.

Physicians: Drs. Bryan BienvenuVince CataldoDavid HansonKellie SchmeeckleJoseph ShowsDerrick SpellSiva Yadlapati and Lauren Zatarain;  James Carinder and Jack SauxRobert Gamble and Naveed Khan.

Offered in: Baton Rouge, Covington, Houma

Trial Number: SWOG 1207

Title: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk Hormone Receptor-Positive and HER2/neu Negative Breast Cancer; e3 Breast Cancer Study—Evaluating Everolimus with Endocrine Therapy +

Purpose: The primary objective of this study is to compare whether the addition of one year of everolimus (10 mg daily) to standard adjuvant endocrine therapy improves invasive disease-free survival (IDFS) in patients with high-risk, hormone-receptor (HR) positive and HER2-negative breast cancer

Physicians: Drs. Bryan BienvenuDavid HansonKellie SchmeeckleDerrick SpellJames CarinderJack SauxRobert GambleNaveed KhanVince CataldoJoseph ShowsSiva Yadlapati and Lauren Zatarain.

Offered in: Baton Rouge, Covington, Houma

Trial Number: SWOG 1418

Title: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor- Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neodajuvant Chemotherapy

Purpose: The primary objective is to compare invasive disease-free survival (IDFS) of patients with triple-negative breast cancer (TNBC) who have either >1 cm residual invasive breast cancer and/or positive lymph nodes (>ypN+) after neoadjuvant chemotherapy randomized to receive 1 year of MK-3475 (pembrolizumab) adjuvant therapy compared to no MK-3475 (pembrolizumab), in both the entire study population and also in the PD-L1 positive subset.

Physicians:  Drs. Bryan BienvenuDavid HansonKellie SchmeeckleDerrick SpellJames CarinderJack SauxRobert GambleNaveed KhanVince CataldoJoseph ShowsSiva Yadlapati and Lauren Zatarain.

Offered in: Baton Rouge, Covington, Houma